Rising dispensation of prescription opioids confirmed

August 20, 2011

(Medical Xpress) -- An investigative team led by Simon Fraser University health sciences professor Benedikt Fischer has established that starkly increasing prescription of strong opioids (POs) is driving up dispensation of the painkillers in Canada.

Fischer, also the CIHR/PHAC applied public health chair, notes POs are essential medication for treating severe and chronic pain. But, in recent years, they have been associated with strongly increasing (i.e., misuse and treatment admissions) and mortality (i.e., ) in Canada.

The study, Differences and over-time changes in levels of prescription opioid analgesic dispensing from retail pharmacies in Canada, analyzes dispensing data for opioids-related prescriptions. It is based on a of 2,700 retail pharmacies in 10 provinces between 2005 and 2010. The Pharmacoepidemiology and Drug Safety Journal published the study’s results online in its July 2011 issue.

Based on an analysis of defined daily doses (DDD) of weak and strong POs per 1,000 people set by the World Health Organization (WHO), Canada’s dispensation of the drugs increased by 13.1 per cent. The amount of all dispensed POs rose from 20.3 DDD/1,000 people in 2005 to 23.0 DDD/1,000 people in 2010.

While the volume of dispensed strong POs rose by 42.1 per cent (7.6 to 10.8 DDD/1,000 people), the volume of weak ones dropped slightly by 4.4 per cent (12.7 to 12.2 DDD/1,000 people).

Based on WHO standards, the researchers defined strong POs as hydrocodone, hydromorophone, oxycodone, fentanyl, meperidine, methadone and morphine. The WHO defines codeine and its combination products as weak POs.

The research team included SFU adjunct professor Wayne Jones from the Centre for Applied Research in Mental Health and Addiction (CARMHA) and University of Toronto researchers Murray Krahn and Juergen Rehm.

North America has the highest POs-dispensation rate in the world and previous studies indicate increased dispensation of the is linked to increased POs-related illnesses and deaths. Governments are developing policy measures on how to reduce POs-related harms to public health. They include improved prescription monitoring and guidelines for opioids.

Given harm-related issues and that little is known about why POs dispensation is increasing, the study has a warning.

“Canada currently finds itself at a major policy and practice development juncture in regard to opioid use that, on the one hand, ought to maximize availability of opioid-supported care for chronic and severe pain with optimal standards and outcomes, while minimizing rapidly rising opioid-related problems and harms...

“The quantity and quality of opioids dispensed — different as these are between Canadian provincial jurisdictions — undoubtedly constitute a crucial variable in this challenge, yet key data are currently missing to guide decision making on the basis of evidence. This issue urgently requires further targeted investigation.”

Explore further: Simulated patient study sheds new light on antibiotic use in India

Related Stories

Treatment options for opioid addiction are expanding

August 10, 2016

In the past two decades, the devastation associated with opioid addiction has escaped the relative confines of the inner city and extended to suburban and rural America. Due in large part to the proliferation of prescription ...

What's the price of a hepatitis C cure?

August 4, 2016

Sofosbuvir is one of a number of new direct-acting antiviral drugs revolutionising the care of people living with hepatitis C. Combinations of two or three hepatitis C virus direct-acting antiviral drugs taken for 8-24 weeks ...

Air pollution affects young people's psychiatric health

June 8, 2016

New research from Umeå University indicates that dispensed medication for psychiatric diagnosis can be related to air polution concentrations. The study covers a large part of the Swedish population and has been published ...

Good news for people with osteoporosis

July 25, 2016

When it comes to your bone health, the benefits of alendronate outweigh the risks, Associate Professor Daniel Prieto-Alhambra from the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences tells Jo ...

Recommended for you

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.